Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) EBT Margin (2017 - 2025)

Protagonist Therapeutics' EBT Margin history spans 9 years, with the latest figure at 594.24% for Q4 2025.

  • For Q4 2025, EBT Margin fell 67525.0% year-over-year to 594.24%; the TTM value through Dec 2025 reached 282.05%, down 34721.0%, while the annual FY2025 figure was 282.05%, 34636.0% down from the prior year.
  • EBT Margin for Q4 2025 was 594.24% at Protagonist Therapeutics, up from 834.87% in the prior quarter.
  • Across five years, EBT Margin topped out at 1031.57% in Q4 2021 and bottomed at 4768.22% in Q2 2022.
  • The 5-year median for EBT Margin is 358.2% (2021), against an average of 564.52%.
  • The largest YoY upside for EBT Margin was 4212369bps in 2021 against a maximum downside of -1011383bps in 2021.
  • A 5-year view of EBT Margin shows it stood at 1031.57% in 2021, then crashed by -103bps to 30.46% in 2022, then soared by 1069bps to 295.11% in 2023, then crashed by -73bps to 81.01% in 2024, then crashed by -834bps to 594.24% in 2025.
  • Per Business Quant, the three most recent readings for PTGX's EBT Margin are 594.24% (Q4 2025), 834.87% (Q3 2025), and 623.86% (Q2 2025).